Qiagen N.V. (QGEN) Stock Rating Reaffirmed by Cowen and Company
Qiagen N.V. (NASDAQ:QGEN)‘s stock had its “hold” rating reissued by investment analysts at Cowen and Company in a research report issued to clients and investors on Friday. They presently have a $33.00 price target on the stock. Cowen and Company’s price objective suggests a potential downside of 2.08% from the company’s previous close.
Several other equities analysts have also recently commented on the stock. Morgan Stanley restated an “overweight” rating and issued a $37.00 target price (up from $36.00) on shares of Qiagen N.V. in a research report on Monday, July 10th. Zacks Investment Research upgraded shares of Qiagen N.V. from a “sell” rating to a “hold” rating and set a $38.00 target price for the company in a research report on Wednesday, July 12th. Wells Fargo & Company restated a “market perform” rating and issued a $31.00 target price (up from $28.00) on shares of Qiagen N.V. in a research report on Thursday, July 13th. Bank of America Corporation restated a “neutral” rating and issued a $36.00 target price (up from $33.00) on shares of Qiagen N.V. in a research report on Friday, July 21st. Finally, TheStreet cut shares of Qiagen N.V. from a “b” rating to a “c+” rating in a research report on Thursday, July 27th. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $33.28.
Shares of Qiagen N.V. (NASDAQ QGEN) traded down $0.56 during mid-day trading on Friday, hitting $33.70. The stock had a trading volume of 1,323,960 shares, compared to its average volume of 1,666,568. The firm has a market capitalization of $7.68 billion, a PE ratio of 27.86 and a beta of 1.13.
TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/03/qiagen-n-v-qgen-stock-rating-reaffirmed-by-cowen-and-company.html.
A number of hedge funds have recently added to or reduced their stakes in the stock. Oppenheimer Asset Management Inc. increased its position in Qiagen N.V. by 0.5% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock worth $133,000 after purchasing an additional 20 shares in the last quarter. M&T Bank Corp grew its holdings in Qiagen N.V. by 2.7% during the 2nd quarter. M&T Bank Corp now owns 8,155 shares of the company’s stock worth $273,000 after acquiring an additional 215 shares during the last quarter. Quadrant Capital Group LLC grew its holdings in Qiagen N.V. by 4.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock worth $183,000 after acquiring an additional 225 shares during the last quarter. QS Investors LLC grew its holdings in Qiagen N.V. by 1.7% during the 2nd quarter. QS Investors LLC now owns 13,594 shares of the company’s stock worth $456,000 after acquiring an additional 226 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado grew its holdings in Qiagen N.V. by 3.5% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 7,214 shares of the company’s stock worth $242,000 after acquiring an additional 246 shares during the last quarter. Institutional investors and hedge funds own 60.35% of the company’s stock.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.